MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Maze Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$29.70+2.17 (+7.88%)

Close on Oct 19, 2026

Market cap: $1.75B
P/E (TTM): –
Dividend yield: –

Maze Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Revenue	–	168
Research & Development	108	83
General & Administrative	34	26
Operating Expenses	143	110
Operating Income	-143	58
Asset Impairment Charges	0	0
Pretax Income	-131	53
Income Tax Expense	0	1.17
Net Income incl. Noncontrolling Interests	-131	52
Net Income	-131	52
Net Income to Common	-131	3.41
EPS (Basic)(per share)	-3.05	1.42
EPS (Diluted)(per share)	-3.05	1.25
Shares Outstanding (Basic, Weighted)(shares)	43	2.40
Shares Outstanding (Diluted, Weighted)(shares)	43	2.73

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -599.0%

Financial strength

Current ratio: 18.31
Debt to equity: 0.09
Debt to assets: 7.3%
Cash to current liabilities: 882.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.87
Dividend yield: –